Skip to main content
Clinical studies· 4 min read

hPG80 and prognosis: understanding the observed associations

In people already receiving care for cancer, high hPG80 levels are associated with less favourable clinical outcomes. A statistical association does not predict an individual's course.¹

Detection and prognosis: two different questions

Detection studies compare hPG80 levels in people with cancer with those in healthy people. Prognostic studies ask a different question: in people already receiving care for cancer, is the level associated with how the disease progresses?¹

Two adults walking side by side in a green space
An individual journey that cannot be reduced to a blood level.

The association described between a high level and less favourable outcomes applies to groups of patients. It does not mean that the level alone determines how the disease will progress, or that it can predict what will happen to an individual.¹

Metastatic kidney cancer: an association with survival

In metastatic kidney cancer, meaning cancer that has spread to other parts of the body, a study examined the link between plasma hPG80 levels and overall survival. Overall survival is the length of time the people being followed remain alive, regardless of the cause of any death.²

High levels are associated with poorer survival in the population studied. This finding describes a statistical relationship at group level: it does not indicate an individual's life expectancy.²

Liver cancer: a marker studied alongside other medical information

A study of hepatocellular carcinoma, a cancer that starts in liver cells, evaluated hPG80 as a marker associated with clinical outcomes. High levels are associated with less favourable outcomes.³

The researchers also studied the value of combining hPG80 with alpha-fetoprotein, another blood marker used in this setting. Interpretation takes account of the full medical follow-up, including the characteristics of the cancer and the condition of the liver.³

Breast cancer: studying a link with recurrence and survival

In a cohort of people with breast cancer, mostly at an early stage, pretreatment hPG80 levels were studied in relation to recurrence and survival.⁴

High levels are associated with less favourable outcomes within this cohort. This observation does not replace the other factors that guide follow-up, such as tumour characteristics and treatments received.⁴

What these observations mean for you

These publications concern people who already have cancer. Their findings cannot be applied directly to someone with no symptoms taking a test that aids early detection.²³⁴

A high level alone cannot establish that the outcome will be unfavourable. hPG80 is not a tool for predicting an individual's prognosis: the doctor interprets the result alongside the clinical examination, other tests and the person's history.²³⁴

If you are already receiving care for cancer, your medical team remains your point of contact for discussing this research and its relevance to your care.²³⁴

Prevonco

Prevonco is currently available in France only.

An aid to the early detection of 16 cancers

No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.

Pre-register for free →